Serum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary Report

Abstract

Background: Preclinical research has suggested that the endocannabinoid system may be involved in the etiology and/or treatment of depression; however, there are no published studies examining circulating endocannabinoid content in patients with clinical depression.

Methods: This study examined the endocannabinoids (anandamide; AEA) and 2-arachidonylglycerol (2-AG) in serum from ambulatory, medication-free female patients diagnosed with minor or major depression, and in controls matched for demographic characteristics.

Results: Serum 2-AG content was significantly decreased in patients diagnosed with major depression, and this decrease was correlated significantly and negatively with duration of the depressive episode, such that 2-AG content was progressively lower the longer the depressive episode. While AEA was not associated with major depression per se, a strong negative correlation was found between serum AEA content and Hamilton ratings for cognitive and somatic anxiety, suggesting that AEA content may relate to the anxiety dimension of affective disorders. In subjects with minor depression, serum AEA was significantly elevated, with 2-AG content demonstrating a similar, but statistically insignificant trend.

Discussion: These are the first clinical data to indicate that the endocannabinoid system may be disturbed in affective disease, and suggest that future research is required to determine the relevance of these changes with respect to disease manifestation and pharmacotherapy.

References

• 1 American Psychiatric Association .Diagnostic and statistical manual of mental disorders 4th ed. Washington DC: American Psychiatric Association 1994
• 2 Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice.  Life Sci. 2004;  75 2959-2970
• 3 Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M. et al . The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.  J Clin Invest. 2003;  112 423-431
• 4 Freedland KE, Skala JA, Carney RM, Raczynski JM, Taylor CB, Mendes de Leon CF. The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity.  Psychosom Med. 2002;  64 897-905
• 5 Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs?.  Trends Mol Med. 2003;  9 474-478
• 6 Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J. et al . Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.  Neuropsychopharmacology. 2004;  29 2108-2114
• 7 Glaser ST, Gatley SJ, Gifford AN. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain.  J Pharmacol Exp Ther. 2006;  316 1088-1097
• 8 Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M. et al . Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.  Proc Natl Acad Sci USA. 2005;  102 18620-18625
• 9 Gonzalez S, Fernandez-Ruiz J, Di Marzo V, Hernandez M, Arevalo C, Nicanor C. et al . Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.  Drug Alcohol Depend. 2004;  74 159-170
• 10 Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.  Biol Psychiatry. 2005;  57 261-267
• 11 Gruber AJ, Pope Jr HG, Brown ME. Do patients use marijuana as an antidepressant?.  Depression. 1996;  4 77-80
• 12 Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test.  Eur Neuropsychopharmacol. 2005;  15 593-599
• 13 Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?.  Behav Pharmacol. 2005;  16 333-352
• 14 Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ. et al . Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress.  Neuropsychopharmacology. 2005;  30 508-515
• 15 Hill MN, Karacabeyli ES, Gorzalka BB. Estrogen recruits the endocannabinoid system to modulate emotionality.  Psychoneuroendocrinology. 2007;  32 350-357
• 16 Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods.  Eur Psychiatry. 2002;  17 ((Suppl 3)) 294-299
• 17 Holsboer F. The corticosteroid receptor hypothesis of depression.  Neuropsychopharmacology. 2000;  23 477-501
• 18 Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB. et al . Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims.  Mol Psychiatry. 2004;  9 184-190
• 19 Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A. et al . Modulation of anxiety through blockade of anandamide hydrolysis.  Nat Med. 2003;  9 76-81
• 20 Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L. et al . The cannabinoid system and immune modulation.  J Leukoc Biol. 2003;  74 486-496
• 21 Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J. et al . Endocannabinoids as cardiovascular modulators.  Chem Phys Lipids. 2000;  108 159-168
• 22 Leonard BE, Song C. Stress and the immune system in the etiology of anxiety and depression.  Pharmacol Biochem Behav. 1996;  54 299-303
• 23 Lopez JF, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression.  Biol Psychiatry. 1998;  43 547-573
• 24 Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG. et al . The endogenous cannabinoid system controls extinction of aversive memories.  Nature. 2002;  418 530-534
• 25 Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour.  Psychopharmacology. 2002;  159 379-387
• 26 MacPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE. Cannabimimetic effects of osteopathic manipulative treatment.  J Am Osteopath Assoc. 2005;  105 283-291
• 27 Maechoulam R, Fride E, Di Marzo V. Endocannabinoids.  Eur J Pharmacol. 1998;  359 1-18
• 28 Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS. et al . The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity.  J Lipid Res. 2005;  46 342-349
• 29 Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.  J Pharmacol Exp Ther. 2006;  318 304-311
• 30 Radloff LS. The CES-D scale: A self-report depression scale for research in the general population.  J App Psychol Meas. 1977;  1 385-401
• 31 Robins LN, Helzer JE, Croughan J, Ratcliff K. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.  Arch Gen Psychiatry. 1981;  38 381-389
• 32 Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice.  Psychopharmacology. 2004;  176 223-232
• 33 Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS. et al . Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice.  Behav Pharmacol. 2003;  14 573-582
• 34 Song C, Horrobin DF, Leonard BE. The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats.  Pharmacopsychiatry. 2006;  39 88-99
• 35 Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR. et al . Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study.  JAMA. 1994;  272 1749-1756
• 36 Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP. et al . The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.  Br J Pharmacol. 2003;  138 544-553
• 37 Vaidya VA, Duman RS. Depresssion emerging insights from neurobiology.  Br Med Bull. 2001;  57 61-79
• 38 Williams JB. A structured interview guide for the Hamilton Depression Rating Scale.  Arch Gen Psychiatry. 1988;  45 742-747
• 39 Willoughby KA, Moore SF, Martin BR, Ellis EF. The biodisposition and metabolism of anandamide in mice.  J Pharmacol Exp Ther. 1997;  282 243-247
• 40 Yukimasa T, Yoshimura R, Tamagawa A, Uozumi T, Shinkai K, Ueda N. et al . High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors.  Pharmacopsychiatry. 2006;  39 52-59

Correspondence